These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 35297969)

  • 1. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
    Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
    JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
    Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V
    JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa.
    Chiwandire N; Walaza S; von Gottberg A; Wolter N; Du Plessis M; Moosa F; Groome MJ; Nel J; Variava E; Dawood H; Makhasi M; Feldstein LR; Marcenac P; Lafond KE; Samuels AM; Cohen C
    Int J Epidemiol; 2024 Aug; 53(5):. PubMed ID: 39305220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covid-19 Vaccine Effectiveness in New York State.
    Rosenberg ES; Dorabawila V; Easton D; Bauer UE; Kumar J; Hoen R; Hoefer D; Wu M; Lutterloh E; Conroy MB; Greene D; Zucker HA
    N Engl J Med; 2022 Jan; 386(2):116-127. PubMed ID: 34942067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
    Lewis NM; Self WH; Gaglani M; Ginde AA; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Ghamande SA; McNeal TA; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Busse LW; Lohuis CCT; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Lauring AS; Halasa N; Chappell JD; Grijalva CG; Rice TW; Rhoads JP; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Adams K; Patel MM; Tenforde MW;
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S159-S166. PubMed ID: 35675695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Van Dromme I; Spiessens B; Vingerhoets J; Custers J; Scheper G; Robb ML; Treanor J; Ryser MF; Barouch DH; Swann E; Marovich MA; Neuzil KM; Corey L; Stoddard J; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2022 Mar; 386(9):847-860. PubMed ID: 35139271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Bekker LG; Garrett N; Goga A; Fairall L; Reddy T; Yende-Zuma N; Kassanjee R; Collie S; Sanne I; Boulle A; Seocharan I; Engelbrecht I; Davies MA; Champion J; Chen T; Bennett S; Mametja S; Semenya M; Moultrie H; de Oliveira T; Lessells RJ; Cohen C; Jassat W; Groome M; Von Gottberg A; Le Roux E; Khuto K; Barouch D; Mahomed H; Wolmarans M; Rousseau P; Bradshaw D; Mulder M; Opie J; Louw V; Jacobson B; Rowji P; Peter JG; Takalani A; Odhiambo J; Mayat F; Takuva S; Corey L; Gray GE; ;
    Lancet; 2022 Mar; 399(10330):1141-1153. PubMed ID: 35305740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Fennema H; Spiessens B; Offergeld K; Scheper G; Taylor KL; Robb ML; Treanor J; Barouch DH; Stoddard J; Ryser MF; Marovich MA; Neuzil KM; Corey L; Cauwenberghs N; Tanner T; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2021 Jun; 384(23):2187-2201. PubMed ID: 33882225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
    Bello-Chavolla OY; Antonio-Villa NE; Valdés-Ferrer SI; Fermín-Martínez CA; Fernández-Chirino L; Vargas-Vázquez A; Ramírez-García D; Mancilla-Galindo J; Kammar-García A; Ávila-Funes JA; Zúñiga-Gil CH; García-Grimshaw M; Ceballos-Liceaga SE; Carbajal-Sandoval G; Montes-González JA; Zaragoza-Jiménez CA; García-Rodríguez G; Cortés-Alcalá R; Reyes-Terán G; López-Gatell H; Gutiérrez-Robledo LM
    Int J Infect Dis; 2023 Apr; 129():188-196. PubMed ID: 36775188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
    Lin DY; Gu Y; Xu Y; Wheeler B; Young H; Sunny SK; Moore Z; Zeng D
    JAMA; 2022 Oct; 328(14):1415-1426. PubMed ID: 36155617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.
    Kompaniyets L; Wiegand RE; Oyalowo AC; Bull-Otterson L; Egwuogu H; Thompson T; Kahihikolo K; Moore L; Jones-Jack N; El Kalach R; Srinivasan A; Messer A; Pilishvili T; Harris AM; Gundlapalli AV; Link-Gelles R; Boehmer TK
    Clin Infect Dis; 2023 May; 76(10):1753-1760. PubMed ID: 36750643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D
    N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
    Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.